» Authors » Arthur Kavanaugh

Arthur Kavanaugh

Explore the profile of Arthur Kavanaugh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 370
Citations 18125
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Westhovens R, Winthrop K, Kavanaugh A, Greenwald M, Dagna L, Cseuz R, et al.
RMD Open . 2025 Jan; 11(1). PMID: 39884731
Objectives: DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials. Methods: Eligible patients...
2.
Moazamian D, Shaterian Mohammadi H, Athertya J, Daskareh M, Ma Y, Guma M, et al.
Eur J Radiol . 2024 Dec; 183:111841. PMID: 39667119
Purpose: This cross-sectional study investigates the utility of the quantitative ultrashort echo time (UTE) adiabatic T (UTE-Adiab-T) magnetic resonance imaging (MRI) in detecting potential differences in Achilles tendons and entheses...
3.
Kavanaugh A, Coates L, Mease P, Nowak M, Hippeli L, Lehman T, et al.
Rheumatology (Oxford) . 2024 Oct; PMID: 39423145
Objectives: Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059),...
4.
Gossec L, Coates L, Gladman D, Aelion J, Vasandani J, Pinter A, et al.
Ann Rheum Dis . 2024 Aug; 83(11):1480-1488. PMID: 39164067
Objectives: Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods: FOREMOST (NCT03747939) was a phase 4...
5.
Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K, et al.
ACR Open Rheumatol . 2024 Aug; 6(11):736-745. PMID: 39087872
Objective: We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient-reported outcomes (PROs), including quality of life (QoL) measures, in patients with...
6.
Ayan G, Aydin S, Coates L, Eder L, Gladman D, Helliwell P, et al.
J Rheumatol . 2024 Jul; 51(Suppl 2):65-69. PMID: 39009384
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, members were updated on a number of ongoing activities during the key project update...
7.
Murillo-Saich J, Coras R, Ramirez J, Quesada-Masachs E, Sala-Climent M, Eschelbach K, et al.
Arthritis Rheumatol . 2024 Mar; 76(8):1230-1242. PMID: 38508862
Objective: Oxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation and may remain overexpressed in refractory synovitis. In plasma, they could also be biomarkers of synovial...
8.
Taylor P, Kavanaugh A, Nash P, Pope J, Pongratz G, Fautrel B, et al.
RMD Open . 2024 Mar; 10(1). PMID: 38479751
Objective: This post hoc analysis of the FINCH 1-3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy...
9.
Mease P, Ogdie A, Tesser J, Shiff N, Zhao R, Chakravarty S, et al.
ACR Open Rheumatol . 2024 Feb; 6(5):304-311. PMID: 38417434
Objective: Evaluate patient-reported outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. Methods: This analysis includes registry...
10.
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, et al.
Rheumatology (Oxford) . 2024 Feb; 63(11):3115-3123. PMID: 38341669
Objectives: To assess the frequency of simultaneous distal interphalangeal (DIP) joint disease and adjacent nail psoriasis (finger unit) among patients with psoriatic arthritis (PsA) and compare the efficacy of the...